Glucagon-like peptide-1 (GLP-1)
PreclinicalPeptide
Novo NordiskGlucagon-like peptide-1 (GLP-1) is one of 36 small molecule programs targeting Hyperinsulinism. It is currently in Preclinical.
2
Indications
1
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
171 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Routine Treatment
GSKPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Preclinical[1]
- Company